Organon (OGN) EBIT (2020 - 2026)

Organon (OGN) has reported EBIT for 7 consecutive years, with $235.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT fell 1.67% year-over-year to $235.0 million; the TTM figure through Mar 2026 stood at $1.1 billion (down 14.88% YoY), while the FY2025 annual figure was $1.1 billion, up 569.23% from the prior year.
• EBIT came in at $235.0 million for Q1 2026 at Organon, up from $210.0 million in the prior quarter.
• The five-year high for EBIT was $411.0 million in Q3 2024, with the low at -$579.0 million in Q4 2023.
• Average EBIT over 5 years is -$58.4 million, with a median of -$119.0 million recorded in 2022.
• Across the five-year window, EBIT slumped 189.92% in 2023 and surged 200.0% in 2024, its largest moves.
• Year by year, EBIT stood at -$483.0 million in 2022, then slipped by 19.88% to -$579.0 million in 2023, then surged by 149.74% to $288.0 million in 2024, then declined by 27.08% to $210.0 million in 2025, then gained by 11.9% to $235.0 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $235.0 million, $210.0 million, and $358.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.